Physician profile
Nancy E Wells
NPI 1891709978
$46,623.25
in general payments reported to CMS, 2019-2025
30 companies · $3,813 in 2025
The $3,813 reported for 2025 was more than what 99% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $8,602 · 2022: $17K · 2023: $10K · 2024: $6,688 · 2025: $3,813.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $19K · Food and Beverage: $2,007 · Education: $98.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $18,864.25 |
| Food and Beverage | $2,007.44 |
| Education | $98.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $38,681.58 | 2021-2025 | Nexplanon, Nuvaring |
| Merck Sharp & Dohme LLC | $4,758.05 | 2021 | |
| Daiichi Sankyo INC. | $551.04 | 2021-2025 | Injectafer |
| Abbvie INC. | $500.45 | 2021-2025 | |
| Astellas Pharma US INC | $336.40 | 2023-2025 | Veozah |
| Evofem Biosciences, INC. | $223.83 | 2021-2024 | Phexxi |
| Pfizer INC. | $189.76 | 2021-2025 | |
| Mayne Pharma Commercial LLC | $160.39 | 2022-2025 | |
| Aspira Women'S Health INC | $152.28 | 2021-2022 | |
| Exeltis, USA INC. | $151.57 | 2021-2025 | Slynd |
| Sumitomo Pharma America, INC. | $141.81 | 2023-2025 | Myfembree, Gemtesa |
| Sage Therapeutics, LLC | $90.36 | 2022-2025 | Zurzuvae |
| Myriad Women'S Health, INC. | $68.95 | 2023 | Myrisk |
| Dexcom, INC. | $64.67 | 2025 | Dexcom G6 Transmitter |
| Millicent US INC | $64.28 | 2024-2025 | Intrarosa, Femlyv, Femring |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $60.74 | 2023 | Wegovy |
| Amgen INC. | $58.30 | 2021-2025 | Evenity, Prolia |
| Hologic Sales and Service, LLC | $50.82 | 2024-2025 | Myosure Tissue Removal Device, Fluent Fluid Management System, Novasure |
| Lupin INC. | $40.72 | 2021 | |
| Shield Therapeutics INC | $37.18 | 2024-2025 | |
| Scynexis, INC. | $35.02 | 2022 | |
| Lilly USA, LLC | $33.88 | 2025 | Zepbound |
| Therapeuticsmd, INC. | $31.57 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $27.43 | 2024-2025 | |
| Davol INC. | $25.77 | 2024 | Arista Ah Flexitip |
| Supernus Pharmaceuticals, INC. | $24.00 | 2025 | Qelbree |
| Smith+Nephew, INC. | $18.17 | 2024 | Pico 14 |
| Agile Therapeutics, INC. | $17.71 | 2023 | Twirla |
| Avion Pharmaceuticals | $13.81 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.71 | 2023 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Wells listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.